Remyelination and neuroprotective effects of alemtuzumab therapy in patients with multiple sclerosis

Alemtuzumab therapy may facilitate remyelination in patients with multiple sclerosis

Multiple sclerosis (MS) is a demyelinating, inflammatory and potentially degenerative disorder of the central nervous system. Whereas, an initial event triggers immune-mediated demyelination in MS, in the secondary progressive phase, axonal degeneration is thought to be due to impaired axo-glial interaction, which leads to a gradual worsening of the disability. In the development of an efficient therapeutic strategy for MS, stimulating or enhancing remyelination is important because remyelination leads to improvement in impulse transmission and metabolic support to the underlying axon.1 Clemastine fumarate and opicinumab, which both target remyelination, have been reported to show reduced visual evoked potentials (VEP) latency in patients with MS and optic neuritis, respectively.1 Alemtuzumab, a humanised monoclonal antibody against the CD52 antigen, has been reported to be associated with disease stabilisation in patients with highly active relapsing-remitting MS.2 Wang…

Read article at journal's website

Related Articles

Responses

Your email address will not be published. Required fields are marked *